Company Update (NYSE:BMY): Bristol-Myers Squibb to Present New Overall Survival Data for Opdivo® (nivolumab) as Monotherapy and in Combination with Yervoy® (ipilimumab) at the AACR 2016 Annual Meeting

[Business Wire] – Bristol-Myers Squibb Company today announced that new clinical research data for two of its Immuno-Oncology medicines — Opdivo and Yervoy — will be presented at the American Association for Cancer Research 2016 Annual Meeting in New Orleans, LA, from April 16-20. Read more on this. Bristol-Myers Squibb Company (BMY) , with a current value of $104.57B, started the session at $63.38. Shares have traded today between $62.21 and $64.32 per share and has traded between $51.82 and $70.87 over the past year. BMY shares are currently priced at 26.76x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s 2.70x earnings multiple for the same period. And for income investors, the company pays shareholders $1.52 per share annually in dividends, yielding 2.34%. In a review of the consensus earnings estimate this quarter, 18 sell-side analysts are looking at $0.63 per share, which would be $0.08 worse than the year-ago quarter and a $0.04 sequential increase. In looking at the bigger picture, the full-year EPS estimate of $2.38 would be a $0.37 improvement when compared to the previous year’s annual results. The quarterly earnings estimate is predicated on a consensus revenue forecast of $4.19 Billion. If reported, that would be a 3.71% increase over the year-ago quarter. Recently, Berenberg upgraded BMY from Hold to Buy (Jan 22, 2016). Previously, Piper Jaffray upgraded BMY from Underweight to Neutral. When considering if perhaps the stock is under or overvalued, the average price target is $72.62, which is 14.58% above where the stock opened this morning. See more in (NYSE:BMY) Similar Articles: Market Update (NYSE:BMY): REPEAT/ Bristol-Myers Squibb’s Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen Receives Expanded FDA Approval in Unresectable or Metastatic Melanoma Across BRAF Status1 Company Update (NYSE:BMY): Bristol-Myers Squibb to Present New Data for Opdivo (nivolumab) in Advanced Melanoma, as Monotherapy and in Combination with Yervoy (ipilimumab), at the Society for Melanoma Research 2015 International Congress Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb’s Opdivo (nivolumab) Recipient of Prix Galien USA 2015 Award for Best Biotechnology Product